

1/21




Fig. 1




Fig. 2

3/21




Fig. 3

4/21




Fig. 4

5/21




Fig. 5A

Fig. 5B

Fig. 5C

6/21

Binding to Activated (CD25⁺) Human Primary T Cells




Fig. 6

7/21

Binding to CD69⁺ Cynomolgus Monkey Primary T Cells









Fig. 7

Fc-Mediated NFAT Activity in Jurkat/NFAT-Luc/hFcγR3a and Jurkat/NFAT-Luc/MfFcγR3a Effector Cells




Antibody Mediation of ADCC Against Jurkat T Cells Engineered to Express Human or Cynomolgus Monkey GITR

Donor 6700R Human Primary NK Cells in the Presence of



Donor 6500V Human Primary NK Cells in the Presence of



Antibody Mediation of ADCC Against Human Primary T Cells

Donor 04003 Human Primary NK Cells in the Presence of




Fig. 10A

Fig. 10B

11/21

Donor 05100 Human Primary NK Cells in the Presence of




Fig. 10C

Fig. 10D

Antibody Mediation of ADCP of Jurkat T Cells Engineered to Express Human or Cynomolgus Monkey GITR

12/21






Fig. 11A

Fig. 11B

Fig. 11C

Antibody Effect on Anti-CD3-Mediated Primary CD4⁺ T-Cell Proliferation



Effect of Anti-GITR Antibody on Human GITR Binding to Human GITR-L




Fig. 13




Fig. 14

mAb1 Does Not Form Immune Complexes Capable of Binding C1q When Incubated with Soluble GTR




Fig. 15B

Fig. 15A

mAb1 in Combination with Cemiplimab Enhances IL-2 Release from Anti-CD3-Stimulated Primary CD3⁺ T Cells in the Presence of Human PD-L1




Fig. 16A




Fig. 16B

Anti-GITR Antibodies CompAb1 and Associated Variants Deplete Intratumoral T regulatory cells and Increase the CD8+ T-cell/ T-regulatory Cell Ratio




Fig. 17

Administration of 1 mg/kg Cemiplimab in Combination with 10 mg/kg mAb1 Results in Greater Reduction in MC38 Tumor Growth Compared with Cemiplimab Alone






Fig. 18

Administration of 1 mg/kg Cemiplimab in Combination with 10 mg/kg mAb1 Results in Higher Frequency of Tumor Clearance Compared with 1 mg/kg Cemiplimab Alone



21/21

Administration of 1 mg/kg Cemiplimab in Combination with 10 mg/kg mAb1 Results in Significantly Greater Survival Compared with Cemiplimab Alone




Fig. 20